Rhythm Pharmaceuticals, Inc.
Method of treating melanocortin-4 receptor pathway-associated disorders

Last updated:

Abstract:

The disclosure is related to a method of treating a disorder, such as Prader Willi Syndrome (PWS), obesity or hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. Also described is method of treating a subject having a deficiency in the pro-opiomelanocortin (POMC)-MC4R pathway, such as a POMC-null or a PCSK-null subject, using a MC4R agonist.

Status:
Grant
Type:

Utility

Filling date:

29 Sep 2016

Issue date:

30 Mar 2021